Publication date: Feb 01, 2025
Laboratory-based findings suggest that Sotrovimab is significantly less effective against emerging CARS-CoV-2 variants, however, clinical data is lacking. Here we examined the effectiveness of sotrovimab, in preventing emergency department (ED) presentation and subsequent hospitalization in high-risk subgroups of patients during the SARS-CoV-2 Delta and Omicron waves in Western Sydney, Australia (n = 515). Risk for ED attendance was comparable in Omicron patients, whether BA. 1 or BA. 2, compared to Delta patients (hazard ratio of 0. 97 [0. 36-2. 64]). These findings highlight the need for caution when using in vitro findings to drive clinical practice, especially when the consequence is to withhold potentially lifesaving treatment.
Open Access PDF
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | emergency |
| drug | DRUGBANK | Etodolac |
| disease | MESH | Infectious Diseases |
| disease | MESH | COVID19 |
| disease | MESH | death |
| disease | MESH | breakthrough infections |
| disease | MESH | recurrence |
| pathway | REACTOME | Reproduction |
| disease | IDO | assay |
| disease | IDO | reagent |
| disease | IDO | symptom |
| drug | DRUGBANK | Oxygen |
| disease | IDO | protein |
| disease | MESH | infection |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | mutation rates |
| disease | MESH | privacy |
| drug | DRUGBANK | Guanosine |
| disease | MESH | Influenza |
| disease | MESH | Blood Cancer |
| disease | MESH | Immunocompromised Patients |
| drug | DRUGBANK | Ritonavir |